Gruppo

Gefitinib, a targeted therapy used for non-small cell lung cancer (NSCLC), is manufactured by several reputable pharmaceutical companies in India. As a key player in the global oncology market, India offers cost-effective yet high-quality Gefitinib formulations, making it a preferred sourcing destination.

Leading Indian manufacturers produce Gefitinib under stringent regulatory guidelines, ensuring compliance with Good Manufacturing Practices (GMP) and approvals from authorities like the FDA, WHO-GMP, and EMA. These manufacturers utilize advanced R&D facilities to enhance drug efficacy while maintaining affordability, catering to both domestic and international markets.

Indian pharmaceutical companies have gained recognition for their ability to provide Gefitinib in various strengths, including 250 mg, the most commonly prescribed dosage. With well-established distribution networks, they export Gefitinib to multiple countries, ensuring timely and seamless supply to healthcare providers and patients worldwide.

For businesses looking to partner with a Gefitinib manufacturer in India, numerous companies offer bulk production, private labeling, and customized packaging options. Whether for local distribution or international export, India remains a trusted hub for high-quality oncology medications, reinforcing its reputation as a leader in pharmaceutical manufacturing.